Orphan designation: tislelizumab Treatment of nasopharyngeal cancer, 21/06/2021 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 26 May 2026 - 11:13

Orphan designation: tislelizumab Treatment of nasopharyngeal cancer, 21/06/2021 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2446

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters